Hydromorphone intranasal - Aegis Therapeutics

Drug Profile

Hydromorphone intranasal - Aegis Therapeutics

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aegis Therapeutics
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Acute pain

Highest Development Phases

  • Preclinical Acute pain

Most Recent Events

  • 26 Oct 2017 Chemical structure information added
  • 13 Oct 2017 Hydromorphone intranasal - Aegis Therapeutics is available for licensing as of 10 Oct 2017. http://aegisthera.com/
  • 10 Oct 2017 Preclinical trials in Acute pain in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top